Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | ESRRG | P62508 | 8/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519055 | 1.00 | ESR1 (0.66) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL5727007 | 1.00 | ESR1 (0.66) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL7109988 | 1.00 | ESR1 (0.66) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL6374444 | 0.99 | ESR1 (0.65) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL6373225 | 0.99 | ESR1 (0.65) | ESR1CYP19A1ESR2LMNAHTR6 | |
| Hydrochloric Acid SCHEMBL7205293 | 0.99 | ESR1 (0.65) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL6373219 | 0.99 | ESR1 (0.65) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL8362771 | 0.97 | ESR1 (0.63) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL8362770 | 0.97 | ESR1 (0.63) | ESR1CYP19A1ESR2LMNAHTR6 | |
| SCHEMBL5726853 | 0.96 | ESR1 (0.72) | ESR1CYP19A1ESR2LMNAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10154970-B2 | Methods for immunomodulation of cancer and infectious disease therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180000747-A1 | METHODS FOR IMMUNOMODULATION OF CANCER AND INFECTIOUS DISEASE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016106146-A1 | METHODS FOR IMMUNOMODULATION OF CANCER AND INFECTIOUS DISEASE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20150321983-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | FERMION OY (FI) | 2015-11-12 | — | — | US | disclosed |
| EP-2909163-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | Fermion Oy (FI) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060640-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | FERMION OY (FI) | 2014-04-24 | — | — | WO | disclosed |
| EP-1056701-B1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORP (FI) | 2003-10-22 | — | — | EP | disclosed |
| US-6395785-B1 | ANTICHOLESTEROL AGENTS; HORMONE REPLACEMENT THERAPY | ORION CORPORATION (FI) | 2002-05-28 | — | — | US | disclosed |
| EP-0900077-B1 | Use of a toremifene metabolite for lowering serum cholesterol level. | ORION CORP (FI) | 2002-02-06 | — | — | EP | disclosed |
| EP-1056701-A1 | E-2- 4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 2000-12-06 | — | — | EP | disclosed |
| US-6037379-A | Serum cholesterol lowering agent | ORION CORPORATION (FI) | 2000-03-14 | — | — | US | disclosed |
| WO-1999042427-A1 | E-2-[4-(4-CHLORO-1,2-DIPHENYL-BUT-1-ENYL)PHENOXY]ETHANOL AND PHARMACEUTICAL COMPOSITIONS THEREOF | ORION CORPORATION (FI) | 1999-08-26 | — | — | WO | disclosed |
| EP-0779808-B1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION YHTYMAE OY (FI) | 1999-08-18 | — | — | EP | disclosed |
| US-5912273-A | COMPOUNDS WITH CHLORO AND HYDROXY GROUPS FOR OSTEOPOROSIS | ORION-YHTYMA OY (FI) | 1999-06-15 | — | — | US | disclosed |
| EP-0900077-A1 | SERUM CHOLESTEROL LOWERING AGENT | ORION-YHTYMÄ OY (FI) | 1999-03-10 | — | — | EP | disclosed |
| US-5750576-A | BONE DISORDERS | ORION-YHTYMA OY (FI) | 1998-05-12 | — | — | US | disclosed |
| WO-1997032574-A1 | SERUM CHOLESTEROL LOWERING AGENT | Orion-Yhtymä Oy (FI) | 1997-09-12 | — | — | WO | disclosed |
| EP-0779808-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION-YHTYMÄ OY (FI) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007402-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Orion-Yhtymä Oy (FI) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10154970-B2 | Methods for immunomodulation of cancer and infectious disease therapy | TLR3, ICOS, TLR9 | ESR1 814/4885CYP19A1 1520/4885ESR2 1589/4885 |
| US-20150321983-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | CYP2F1, OGFR, OPRM1 | ESR1 133/4885CYP19A1 104/4885ESR2 161/4885 |
| US-20180000747-A1 | METHODS FOR IMMUNOMODULATION OF CANCER AND INFECTIOUS DISEASE THERAPY | TLR3, ICOS, TLR9 | ESR1 814/4885CYP19A1 1520/4885ESR2 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.